PML/RAR␣ APL with undifferentiated morphology and stem cell immunophenotype

TO THE EDITOR
Recent clinical trials of acute promyelocytic leukemia (APL) have confirmed a survival benefit for patients treated early with all-trans retinoic acid (ATRA) and chemotherapy as opposed to chemotherapy alone. 1 These trials emphasize the importance of prompt and accurate diagnosis of t(15;17) APL. In most instances, morphological recognition of t(15;17) APL is straightforward due to the presence of hypergranular cells and cells with multiple Auer rods. In the FAB variant of APL there is a paucity of hypergranular cells or cells with multiple Auer rods but the typical contorted nuclear configuration is usually distinctive.
2 Additional variant forms of APL resembling FAB M1, either with infrequent (Ͻ1-5%) 3 or without hypergranular cells 3, 4 have recently been reported. [3] [4] [5] In these atypical cases, diagnosis is established by cytogenetics or fluorescent in situ hybridization (FISH) for t(15;17), or by Southern blot or RT-PCR for PML/RAR␣. We present a case of atypical APL that exemplifies the limitations of using morphological assessment alone for the diagnosis. The case also indicates that transformation caused by PML-RAR␣ can occur in an immature cell with immunophenotypic features of both myeloid and lymphoid lineages consistent with pluripotential differentiation ability. 6 The patient, a 45-year-old male, was referred from a regional hospital with the diagnosis of acute lymphoblastic leukemia (FAB L2) (addendum 3 ). He presented with a 2-week history of pallor, fatigue and tender acneiform lesions on his face, neck and upper back. His past history was unremarkable. Physical examination revealed swelling of the skin overlying the right maxillary sinus and several erythematous papular lesions on the upper torso and face. There was no hepatosplenomegaly or significant adenopathy. There was no gingival hypertrophy and no petechiae or purpura.
Laboratory studies revealed a white blood count of 77.7 × 10 9 /l (normal 4-9.8 × 10 9 /l), hemoglobin 97 g/l (normal 120-180 g/l), platelet count 87 × 10 9 /l (normal 150-450 × 10 9 /l). The white count differential was as follows: blasts 85%, lymphocytes 10% (normal 20-45%) and neutrophils 5% (normal 40-75%). Renal function, electrolytes, calcium, phosphate, uric acid and protein electrophoresis were all normal. The lactate dehydrogenase was 398 U/l (normal 100-220 U/l). The total bilirubin, alkaline phosphatase and gamma glutaryl transferase were normal but the asparate and alanine aminotransferases were 42 U/l and 87 U/l, respectively (normal Ͻ35 U/l for both).
The bone marrow was hypercellular and consisted of undifferentiated blast cells (FAB L2/M1) ( Figure 1 made. Electron microscopy showed primitive immature cells with rare small, round granules. Myeloperoxidase showed an infrequent weakly positive cell.
The international normalized ratio (INR) was 1.5 (normal 0.9-1.2), with an activated partial thromboplastin time (aPTT) of 31 s (normal 25-39 s), thrombin time 13 s (normal 8-12 s) and fibrinogen 1.1 g/l (normal 1.5-4.0 g/l). The D-dimer was Ͼ2000 ng/ml (normal Ͻ500 ng/ml) and the protamine sulfate was positive, consistent with disseminated intravascular coagulation (DIC).
Based on the DIC screen, RT-PCR for PML/RAR␣ transcripts was performed and an amplified band at 220 bp (short form) was noted 3, 5, 8 indicative of t(15;17) APL (Figure 2 ). Cytogenetic analysis showed that, in two of 18 analyzed cells, the 17q arm was shortened in a manner consistent with a 15;17 translocation, but no corresponding abnormality of chromosome 15 could be detected. Southern blot analysis 3 showed RAR␣ rearrangement ( Figure 3 ). The diagnosis of APL was made.
On the fifth day of admission, the patient was started on induction AML therapy consisting of mitoxantrone and cytosine arabinoside in standard doses. Based on results of RT-PCR demonstrating PML-RAR␣ positivity, the patient was started on ATRA 40 mg orally twice daily (45 mg/m 2 per day, 1.7 m 2 ). Fol-
Figure 2
RT-PCR for PML-RAR␣ transcripts. The patient is positive for the short form rearrangement (220 bp).
lowing ATRA administration there was subsequent resolution of DIC over the next 4 days. There was no clinical evidence of ATRA syndrome. Induction therapy was complicated by neutropenic fever, anorexia, diarrhea, oral thrush as well as cellulitis of the Hickman site and both axillae. No bleeding problems were encountered throughout induction therapy.
Upon recovery of peripheral blood counts by day 28, his bone marrow examination was normal. ATRA was discontinued and the patient was discharged home. The patient went on to receive two further consolidations and is currently in complete morphological remission with normal blood counts, 7 months after diagnosis; however, the PML-RAR␣ fusion gene remains positive by RT-PCR. The patient has been restarted on maintenance ATRA therapy for a year.
This case illustrates potential difficulties in diagnosing some cases of APL by morphology alone. It has been suggested that RT-PCR for PML-RAR␣ transcripts be performed on all de novo AML cases, in order to diagnose the infrequent variant form with atypical morphology. 3 Some laboratories might not have the resources to undertake this and in order to restrict RT-PCR to the most likely cases it is suggested that RT-PCR for PML-RAR␣ transcripts be performed on: (1) cases of AML with evidence of DIC; (2) cases with atypical morphology but showing the infrequent/rare hypergranular cell or cell with multiple Auer rod; 3 and (3) on those AML cases with an M3 immunophenotypic profile (CD33
The blast cells of our case showed immaturity confirmed on both immunophenotyping 7 and electron microscopy. Takatsuki et al, 6 using culture experiments, have shown the presence of PML/RAR␣ positive colonies in both CFU-GM and BFU-E, suggesting that transformation caused by PML/RAR␣ takes place at the level of the multipotent stem cell. Our case indicates that APL can also arise in a cell that has pluripotential capacity.
The incidence of undifferentiated t(15;17) APL is probably infrequent and the incidence might vary in different geographical areas. 9 To determine the true incidence of APL, including immature stem cell variants, RT-PCR for PML-RAR␣ transcripts will be performed on all cases of AML in a prospective study in the Hamilton region.
